AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics.

Developer of scientific data management software designed to enhance workplace collaboration. Acquired by PerkinElmer (NYS: PKI) in March 2011.

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform. Acquired by Press Ganey Associates in January 2018.

Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.

Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.

Curoverse developed a genomic and biomedical computing platform. Acquired by Veritas Genetics in August 2017.

CVRx develops an implantable system that delivers baroreflex activation therapy. IPO in June 2021 (NASDAQ: CVRX).

Developer of a technology designed to extract highly sensitive nucleic acid quantification. Acquired by Bio-Rad 2021

Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. IPO in May 2017 (NASDAQ: GTHX) Acquired by Pharmacosmos in 2024

Graybug Vision, Inc. was a clinical-stage ophthalmology company developing sustained-release therapies. IPO in September 2020 (NASDAQ: GRAY).

HistoSonics, Inc. is pioneering a novel, non-invasive therapeutic platform based on histotripsy. Acquired by Bezos Expeditions, Wellington K5 Global 2025

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company pioneering targeted protein degradation. IPO in August 2020 (NASDAQ: KYMR).

Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.

Provider of patient experience platform designed to facilitate the relationship between physicians and patients. Acquired by NextGen 2019

Developer of staffing, communication and schedule management tools designed to modernize staffing processes. Acquired by HealthStream 2020

The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)

Qpex Biopharma is a clinical-stage biopharmaceutical company developing novel anti-infective therapies. Acquired by Shionogi 2023

Rodin Therapeutics was a biotechnology company focused on discovering and developing first-in-class small molecule therapeutics. Acquired by ALKS in Nov 2019

Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. IPO in October 2020 (NASDAQ: STTK)

Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

Viamet Pharmaceuticals is a biotechnology company. Acquired by NovaQuest Capital Management in January 2018.

Vigil Neuroscience is a clinical-stage biotechnology company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
